SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 134 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $102,000 | -62.2% | 11,300 | -50.0% | 0.00% | – |
| Q2 2021 | $270,000 | +365.5% | 22,600 | +391.3% | 0.00% | – |
| Q1 2021 | $58,000 | -85.3% | 4,600 | 0.0% | 0.00% | – |
| Q4 2020 | $395,000 | +797.7% | 4,600 | 0.0% | 0.00% | – |
| Q3 2020 | $44,000 | +4.8% | 4,600 | 0.0% | 0.00% | – |
| Q2 2020 | $42,000 | +180.0% | 4,600 | +100.0% | 0.00% | – |
| Q1 2020 | $15,000 | -21.1% | 2,300 | 0.0% | 0.00% | – |
| Q4 2019 | $19,000 | +850.0% | 2,300 | +1252.9% | 0.00% | – |
| Q3 2019 | $2,000 | -85.7% | 170 | -86.9% | 0.00% | – |
| Q2 2019 | $14,000 | +16.7% | 1,300 | 0.0% | 0.00% | – |
| Q1 2019 | $12,000 | +20.0% | 1,300 | +52.9% | 0.00% | – |
| Q4 2018 | $10,000 | -28.6% | 850 | 0.0% | 0.00% | – |
| Q3 2018 | $14,000 | +16.7% | 850 | 0.0% | 0.00% | – |
| Q2 2018 | $12,000 | +33.3% | 850 | +88.9% | 0.00% | – |
| Q1 2018 | $9,000 | +28.6% | 450 | 0.0% | 0.00% | – |
| Q4 2017 | $7,000 | – | 450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |